通过深度突变扫描对MET受体氨酸激酶的基因酶域抵抗机制进行映射
Gabriella O Estevam1,2, Edmond M Linossi3,4, Jingyou Rao5
1Department of Bioengineering and Therapeutic Sciences, UCSF, San Francisco, CA, United States.
bioRxiv : the preprint server for biology
|July 29, 2024
概括
这项研究对11种抑制剂的MET激酶域突变进行了分析,以确定耐药性和敏感性模式. 通过指导针对MET驱动癌症的向治疗选择,研究结果有助于精准医学.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在MET受体氨酸激酶 (MET) 中的突变驱动各种癌症的瘤发生和耐治疗性.
- 根据特定的突变档案确定最佳的MET导向疗法对于精准医学至关重要.
研究的目的:
- 针对一组MET抑制剂,对MET激酶域变异进行全面的分析.
- 为了确定不同类别的抑制剂的耐药性和敏感化突变.
- 改进MET驱动癌症中抑制剂反应的预测模型.
主要方法:
- 深度突变扫描 (DMS) ~5,764个MET激酶域变体.
- 评估对11种MET激酶域抑制剂的突变生长.
- 增强蛋白质语言模型的生物物理和化学特征,以提高预测.
主要成果:
- 验证了已知的MET耐药性突变,并确定了各类抑制剂中常见的耐药性位点.
- 发现了针对单个抑制剂的独特耐药性和敏感化突变.
- 验证了I型和II型MET抑制剂之间的非交叉耐药性敏感性.
- 改善了蛋白质语言模型对受抑制剂处理的数据集的预测性能.
结论:
- 建立了一个聚合的实验管道,用于识别MET耐药性突变.
- 创建了一个对特定MET向治疗敏感突变的参考词典.
- 为开发下一代MET抑制剂和个性化癌症治疗提供了洞察力.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mismatch Repair
4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


